Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRT-8102 · 1 trial · 2 indications
Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs
Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs
Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (MRT-8102) | EXPERIMENTAL | Single Dose of MRT-8102 |
| Part 1: Single Ascending Dose (Placebo) | PLACEBO_COMPARATOR | Single Dose of Placebo |
| Part 2: Multiple Ascending Dose (MRT-8102) | EXPERIMENTAL | 7-day Daily Dose of MRT-8102 |
| Part 2: Multiple Ascending Dose (Placebo) | PLACEBO_COMPARATOR | 7-day Daily Dose of Placebo |
| Part 3: elevated CRP (MRT-8102) | EXPERIMENTAL | 28-day Daily Dose of MRT-8102 |
| Part 3: elevated CRP (Placebo) | PLACEBO_COMPARATOR | 28-day Daily Dose of Placebo |
| Name | Type | Description |
|---|---|---|
| MRT-8102 | DRUG | Oral capsules |
| Placebo | DRUG | Oral capsules |
Eligibility Criteria: Inclusion Criteria (all parts) * Healthy, adult, male or females 18-65 years of age * Non-smoker who has not used nicotine- and tobacco -containing products for at least 3 months prior to start of study * Able to swallow oral medications * Abstain from caffeine- and methylxan...
MRT-8102 is an investigational small molecule being studied in healthy volunteers and participants at cardiovascular risk with elevated CRP. It is currently in Phase 1 clinical development and is not approved by the FDA.
MRT-8102 targets NEK7, a protein involved in cellular processes. By targeting NEK7, the drug aims to modulate pathways relevant to inflammation and cardiovascular risk, though the exact mechanism is still under investigation in clinical trials.
MRT-8102 is being developed by Monte Rosa Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker GLUE.
MRT-8102 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
MRT-8102 is being studied in a first-in-human, 3-part trial (NCT07119125) in healthy participants and participants at cardiovascular risk with elevated CRP. The trial is active but not recruiting, with an enrollment of 100 participants in the United States.
MRT-8102 is a small molecule that targets NEK7, making it a NEK7 inhibitor. However, it is not known by any other drug names; MRT-8102 is the sole identifier for this investigational compound.